Physician profile
W Lebas
NPI 1144215815
$1,849.84
in general payments reported to CMS, 2019-2025
16 companies · $207 in 2025
The $207 reported for 2025 was more than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $100 · 2020: $357 · 2021: $624 · 2022: $304 · 2023: $122 · 2024: $135 · 2025: $207.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $465.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $464.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $367.57 | 2021-2025 | |
| Teva Pharmaceuticals USA, INC. | $308.55 | 2019-2025 | Ajovy, Austedo |
| Amgen INC. | $267.00 | 2019-2022 | |
| Lilly USA, LLC | $233.09 | 2019-2024 | Emgality |
| Pfizer INC. | $141.71 | 2021-2025 | |
| Lundbeck LLC | $106.59 | 2020-2025 | Vyepti |
| Novartis Pharmaceuticals Corporation | $105.15 | 2020-2021 | |
| Upsher-Smith Laboratories LLC | $75.11 | 2020-2021 | |
| Currax Pharmaceuticals LLC | $56.57 | 2022-2023 | Onzetra Xsail |
| Allergan, INC. | $49.27 | 2020 | |
| Biohaven Pharmaceuticals, INC. | $37.62 | 2021 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $23.12 | 2022 | |
| Assertio Therapeutics, INC. | $22.04 | 2020 | |
| Akcea Therapeutics, INC. | $21.47 | 2021 | |
| Amneal Pharmaceuticals LLC | $20.02 | 2020 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch Health US, LLC | $14.96 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw W Lebas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.